Tebentafusp is a recombinant bispecific protein produced using recombinant DNA technology in Escherichia coli. Its TCR component recognizes a gp100 peptide presented by HLA-A*02:01, while the anti-CD3 component engages T cells.
The approximate molecular weight of tebentafusp is 77 kDa, with a theoretical polypeptide molecular mass of approximately 76.145 kDa.
Tebentafusp is a protein-based therapeutic rather than a conventional small-molecule API. Consequently, its quality evaluation relies on protein characterization, purity, potency, identity, aggregate assessment, and biological quality attributes.
Tebentafusp contains two functional binding domains. The TCR domain binds a gp100 peptide presented by HLA-A*02:01 on tumor cells, while the anti-CD3 scFv binds CD3 on T cells.
This dual binding brings T cells into close proximity with gp100-positive tumor cells and promotes T-cell-mediated cytotoxic activity. The mechanism enables immune recognition of tumor cells that would otherwise be difficult for T cells to recognize directly.
Tebentafusp is an oncology biologic used for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma. The U.S. FDA approved tebentafusp-tebn in January 2022 for this indication.
Its principal pharmaceutical application is therefore targeted cancer immunotherapy involving:
As a recombinant biologic, Tebentafusp API requires a comprehensive analytical characterization program. Typical quality attributes include:
Potency testing should evaluate the functional activity associated with the gp100-HLA-A*02:01 and CD3-targeting mechanism.
Tebentafusp is manufactured using recombinant DNA technology in E. coli. Production of recombinant protein therapeutics requires controlled upstream expression, downstream purification, protein characterization, and appropriate microbiological and biological quality controls.
Manufacturing and release specifications are product- and process-specific and should be established according to the applicable regulatory and quality framework.
Tebentafusp is a recombinant protein therapeutic with an approximate molecular weight of 77 kDa. The main reported pI is approximately 6.3. Unlike conventional small-molecule APIs, parameters such as melting point and conventional organic-solvent solubility are generally not used as primary release characteristics for the finished biologic substance.
The marketed formulation is a clear, colorless to slightly yellowish sterile solution with a formulation pH of approximately 6.5.
Tebentafusp drug substance and drug product require controlled biologic handling and storage conditions appropriate to the validated stability profile.
Packaging should protect the protein from contamination, excessive temperature exposure, light, and other conditions that could affect its quality. Final storage requirements should follow the applicable validated product specification.
Typical documentation associated with Tebentafusp API can include:
A reliable Tebentafusp API manufacturing and development partner should maintain robust biologics manufacturing controls, validated analytical procedures, traceable documentation, and stringent quality systems.
Swapnroop focuses on quality-oriented pharmaceutical and API solutions supported by controlled manufacturing practices and analytical evaluation. Tebentafusp-related specifications can be developed according to customer requirements and applicable regulatory standards.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 0.5% |
| Residue on Ignition | NMT 0.1% |
| pH (1% Solution) | Approximately 6.5 |